tert-butyl dimethylphosphonoylacetate

• 分子结构分类: 有机化合物 - 有机磷化合物 - 亚磷酸三烷基酯
• 英文名称: tert-butyl dimethylphosphonoylacetate
• 英文别名: (dimethoxy-phosphanyloxy)-acetic acid tert-butyl ester；(Dimethoxy-phosphanyloxy)-acetic acid tert-butyl ester；tert-butyl 2-dimethoxyphosphanyloxyacetate
• 化学式: C₈H₁₇O₅P
• 分子量: 224.194
• InChiKey: HCHOHYOAFILGJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl dimethylphosphonoylacetate 在 正丁基锂 、 4 A molecular sieve 、 二异丁基氢化铝 、 pyridinium chlorochromate 作用下， 反应 2.25h， 生成 <2(S)-(2-methyl-3-(tert-butoxycarbonyl)-2(E)-propenyl)-3(S),4(R)-(cyclohexylidenedioxy)tetrahydropyran-5(S)-yl>acetaldehyde
  参考文献：
  名称：

  Enantioselective total synthesis of (-)-monic acid C via carbosulfenylation of a dihydropyran

  摘要：

  DOI：

  10.1021/jo00260a020

文献信息

• INHIBITORS OF BETA AMYLOID PRODUCTION
  申请人：Caggiano Thomas J.

  公开号：US20090023801A1

  公开（公告）日：2009-01-22

  Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R 1 -R 3 are defined herein. Also provided are pharmaceutical compositions containing these compounds and/or prodrugs of these compounds and a physiologically compatible carrier. These compounds are specifically useful for inhibiting beta amyloid production, and treating Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome.

  描述了在与β-淀粉样蛋白产生相关的疾病治疗中有用的新型磺胺化合物，以及它们的制备途径。这些磺胺化合物具有以下结构，其中R1-R3在此定义。还提供了含有这些化合物和/或这些化合物的前药以及与生理兼容载体的药物组合物。这些化合物特别适用于抑制β淀粉样蛋白的产生，并治疗阿尔茨海默病、淀粉样血管病、脑淀粉样血管病、全身淀粉样病、荷兰型遗传性脑出血伴有淀粉样蛋白沉积、包涵体肌炎、轻度认知障碍（MCI）和唐氏综合征。
• [EN] INHIBITORS OF BETA AMYLOID PRODUCTION<br/>[FR] INHIBITEURS DE PRODUCTION DE BÊTA AMYLOÏDE
  申请人：WYETH CORP

  公开号：WO2009012205A1

  公开（公告）日：2009-01-22

  Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R4-R3 are defined herein. Also provided are pharmaceutical compositions containing these compounds and/or prodrugs of these compounds and a physiologically compatible carrier. These compounds are specifically useful for inhibiting beta amyloid production, and treating Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome.